Axsome Therapeutics, Inc.   Report issue

For profit Phase 3 Phase 4
Founded: New York NY United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2015
NCT02504008
First Marketed Drug
2019
solriamfetol (Sunosi)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

AXSOME | AXSOME MALTA | Axsome Therapeutics, Inc.